Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Vile

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2019
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder CancerNicola E Annels, David Mansfield, Mehreen Arif, et al.
Nature Communications|June 27, 2024
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell responseMason J Webb, Thanich Sangsuwannukul, Jacob van Vloten, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Science Immunology|December 2, 2022
Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cellsMarco Künzli, Stephen D O'Flanagan, Madeleine LaRue, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanomaGalabina Bozhanova, Jehanne Hassan, Lizzie Appleton, et al.
Science Translational Medicine|June 16, 2012
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsRobert A Adair, Victoria Roulstone, Karen J Scott, et al.
Nature Communications|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Nature Communications|July 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Hepatology (Baltimore, Md.)|September 2, 2022
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancersBolni Marius Nagalo, Yumei Zhou, Emilien J Loeuillard, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signalingVictoria Roulstone, Joan Kyula, Elizabeth Appleton, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2019
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder CancerNicola E Annels, David Mansfield, Mehreen Arif, et al.
Nature Communications|June 27, 2024
Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell responseMason J Webb, Thanich Sangsuwannukul, Jacob van Vloten, et al.
Nature Communications|June 26, 2020
Oncolytic virus-derived type I interferon restricts CAR T cell therapyLaura Evgin, Amanda L Huff, Phonphimon Wongthida, et al.
Science Immunology|December 2, 2022
Route of self-amplifying mRNA vaccination modulates the establishment of pulmonary resident memory CD8 and CD4 T cellsMarco Künzli, Stephen D O'Flanagan, Madeleine LaRue, et al.
Journal for Immunotherapy of Cancer|March 26, 2022
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanomaGalabina Bozhanova, Jehanne Hassan, Lizzie Appleton, et al.
Science Translational Medicine|June 16, 2012
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsRobert A Adair, Victoria Roulstone, Karen J Scott, et al.
Nature Communications|May 24, 2025
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Nature Communications|July 15, 2025
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasionVictoria Roulstone, Joan Kyula-Currie, James Wright, et al.
Hepatology (Baltimore, Md.)|September 2, 2022
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancersBolni Marius Nagalo, Yumei Zhou, Emilien J Loeuillard, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signalingVictoria Roulstone, Joan Kyula, Elizabeth Appleton, et al.
Pageof 10